Cowden Syndrome Market Analysis 2019 | Share Analysis, Market Value, Size Estimation, Future Trends and Global Industry Insights
The Cowden Syndrome Market Research Report - Global Forecast
till 2023 delivers a thorough understanding of the market’s present status and
likely future growth trajectory over the forecast period on the basis of the
market’s historical growth trajectory and figures
Cowden syndrome (CS), a clinical disorder and inherited
condition that is characterized primarily by multiple, noncancerous growths
called hamartomas on various parts of the body.
The occurrence of CS can lead to the risk of developing certain types of
cancer including Breast, thyroid, and endometrial cancers.
Although a rare kind of disease, over the past couple of
years, the prevalence of Cowden syndrome seems to be increasing. Besides, it being a risk factor for cancerous
tumors, the Cowden syndrome is taken seriously, and huge investments are
transpired in the development of treatment. With the interventions of advanced
technologies, today, specialists are developing breakthrough therapies &
treatments that are phenomenally close. Therefore, the market for Cowden
syndrome is growing globally.
Acknowledging the traction, the market is vibrating with
currently, Market Research Future (MRFR) in its recently published study report
asserts that the global Cowden syndrome market gaining further prominence will
demonstrate a spectacular growth by 2023, surpassing its previous growth
records in terms of value with a striking 6.7% CAGR during 2017 – 2023.
Evidently, technological advancements transpired into the
field of medical science are providing impetus to the growth of the Cowden
syndrome market further escalating it pervasively. However, efforts of key
market players that are constantly bringing improvements in the treatments are
rather seminal. Hence the market players are the main force driving the market
growth exclusively.
The Cowden
syndrome market still consists of a limited number of treatments; however,
governments of various countries have taken up many initiatives to spread the
awareness and to support the manufacturers for research and development of
drugs, medical devices, and technology. These initiatives are paying off well
by increasing the market size substantially, raising the awareness among people
about the disease and the availability of its treatments.
On the other hand, the side effects and the high cost of the
medicines associated with the treatment are some of the key factors impeding
the market growth. Also, the limited vision, knowledge, and awareness towards
the treatment’s availability are obstructing the market growth of Cowden
syndrome, especially in the underdeveloped regions such as the Middle Eastern
and African region.
Global Cowden Syndrome Market – Segments
The MRFR analysis is segmented into four key dynamics;
By Sites : Breast, Thyroid, Endometrium (uterus),
Colorectal, Kidney, and Skin (melanoma), among others.
By Treatments :
Genetic Testing, Chemotherapy (Anthracyclines, Taxanes, Antimetabolites,
Alkylating Agents and others.), Targeted Therapy (Monoclonal Antibodies,
Tyrosine Kinase Inhibitors, and others.), Surgery & Radiation Therapy,
Hormone Therapy (Selective Estrogen-Receptor Modulators (SERMs), Aromatase
Inhibitors, and others.).
By End-Users : Hospital & Clinics, ambulatory care
centers, and others.
By Regions : North America, Europe, APAC and the
Rest-of-the-World.
Global Cowden Syndrome Market – Regional Analysis
The North American region dominates the global Cowden
syndrome market, accounting for a significant market share. The region is
expected to continue with its dominance throughout the forecast period. The
increasing prevalence of Cowden syndrome and cancer is predominantly driving
the market growth in the region.
Additional factors acting as a tailwind to the market growth
include high healthcare expenditure, huge technological development, and strong
government support for research & development. Simultaneously, the presence of the leading
players and increasing availability of funds are impacting the market growth in
this region, positively.
The European region accounts for the second-largest market
for Cowden syndrome treatment, emerging as another lucrative market, globally.
Germany, backed by its sizeable medical device industry and its vast Cowden
syndrome treatment market is expected to drive the market growth in the region.
Favorable governmental support and initiatives drive the growth in the market
extensively. The proliferating healthcare sector in the region, backed by the
resurging economy is fostering the market growth radiantly.
The Asia Pacific region is emerging as a promising market
for Cowden syndrome treatments owing to the increasing cases of cancer. The
region is expected to escalate rapidly over the forecast period. Factors such
as the huge development opportunities along with the constantly developing
healthcare infrastructure in the Asia Pacific region is propelling the market
growth. Countries such as India and China, backed by the rapidly increasing the
economy and increasing government support are expected to lead the market in
this region.
Global Cowden Syndrome Market Research Report: By Site
(Breast, Thyroid, Colorectal, Kidney, Skin), Treatment (Genetic Testing,
Chemotherapy, Targeted Therapy, Surgery & Radiation Therapy, Hormone
Therapy), End User (Hospital & Clinics) - Forecast till 2023 @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096
Global Cowden Syndrome Market – Competitive Analysis
Cowden syndrome market is highly competitive. The key
strategies traced from the analysis of recent developments of the key players
include product launch, agreement & partnership, acquisition, and
expansion. Key manufacturers utilizing breakthrough manufacturing technology
strive to develop a comprehensive range of safe and reliable solutions
portfolio.
Key Players:
The global cowden syndrome market is driven by some of the
leading players including GlaxoSmithKline Plc. (UK), Novartis AG (Switzerland),
Bayer AG (Germany), Eli Lilly and Company (US), Amgen, Inc. (US), AstraZeneca
Plc. (UK), Sanofi (France), Bristol-Myers Squibb Company (US), AbbVie Inc.
(US), Takeda Pharmaceuticals (Japan), Spectrum Pharmaceuticals Inc. (US),
Pfizer, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co.,
Inc. (US), Janssen Biotech, Inc. (US), Oncomed Pharmaceuticals (US), and
Immunomedics (US).
Industry/Innovation/ Related News:
September 21, 2018 - GlaxoSmithKline Plc. (UK), a leading
global research-based pharmaceutical and healthcare company partnering with the
Tres Cantos Open Lab Foundation (TCOLF), a company addressing the translational
and funding gap existing in Global Health (GH) announce additional £5m funding
for open innovation research in diseases including rear diseases such as Cowden
syndrome impacting the developing world.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of
the industry, MRFR often plans & conducts meet with the industry experts
and industrial visits for its research analyst members.
Contact:
Comments
Post a Comment